EP0518652A1 - Verbindungen und Verfahren zur Behandlung thromboembolischer Störungen - Google Patents

Verbindungen und Verfahren zur Behandlung thromboembolischer Störungen Download PDF

Info

Publication number
EP0518652A1
EP0518652A1 EP92305336A EP92305336A EP0518652A1 EP 0518652 A1 EP0518652 A1 EP 0518652A1 EP 92305336 A EP92305336 A EP 92305336A EP 92305336 A EP92305336 A EP 92305336A EP 0518652 A1 EP0518652 A1 EP 0518652A1
Authority
EP
European Patent Office
Prior art keywords
adduct
derivative
sulfate
group
straight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92305336A
Other languages
English (en)
French (fr)
Other versions
EP0518652B1 (de
Inventor
Philip John Burck
Ronald Eugene Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0518652A1 publication Critical patent/EP0518652A1/de
Application granted granted Critical
Publication of EP0518652B1 publication Critical patent/EP0518652B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention provides an adduct of a human t-PA derivative, wherein said adduct comprises a t-PA derivative that lacks the Finger, Growth Factor and Kringle 1 domains, bound to an amphipathic molecule.
  • the invention also provides methods and compositions for the treatment of thromboembolic disorders.
  • Plasminogen activators are a unique class of enzymes that convert the catalytically inactive zymogen plasminogen to its active enzymatic form, plasmin. Plasmin is a Serine Protease requisite for the dissolution of fibrin (Colleen, D., 1980, Thromb. Haemostasis 43:77-89). Several plasminogen activators are now being.used as in vivo fibrinolytic agents in the treatment of acute myocardial infarction (Tiefenbrunn, et al ., 1989, Fibrinolysis 3:1-15).
  • Tissue plasminogen activator has been the focus of considerable attention because its ability to activate plasminogen is significantly enhanced in the presence of fibrin (Rijken et al. , 1982, J. Biol. Chem. 257:2920-2925), a property that should make it more clot specific when used as an in vivo fibrinolytic agent.
  • the inferred sequence of 527 amino acids comprises five distinct structural domains: a Finger domain; a Growth Factor domain; two Kringle domains; and a Serine Protease domain (Pennica et al. , 1983, Nature 301:214, and Banyai et al. , 1983, FEBS Lett. 163:37-41).
  • a series of deletion mutants of t-PA that comprise the Serine Protease domain and one or more of the other four structural domains of the intact molecule have been constructed (van Zonneveld et al. , 1986, Proc. Natl. Acad. Sci. 83:4670; Erlich et al.
  • mt-PA6 produced by recombinant DNA techniques was found to possess greater fibrinolytic activity and a greater ability to activate thrombus-bound plasminogen than t-PA (Jackson et al. , 1990, Circulation 82:930-940).
  • mt-PA6 is found in two glycosylation forms when produced by eukaryotic cell culture using recombinant DNA techniques. These two glycosylation forms account for the doublet of 40 and 41 kD bands seen when the purified mt-PA6 molecule is analyzed by gel electrophoresis.
  • One of the glycosylation forms Primary mt-PA6 (mt-PA6-P)
  • mt-PA6-P is glycosylated at amino acid 176 (equivalent to amino acid 448 of t-PA) but not at amino acid 11 (equivalent to amino acid 184 of t-PA).
  • the second glycosylation form, Variant mt-PA6 is glycosylated at both amino acids 11 and 276.
  • mt-PA6 lacks the Kringle 1 domain and, therefore, lacks the glycosylation site at amino acid 117 of this domain.
  • mt-PA6-V comprises 10-25% of the mt-PA6 molecules secreted from the Syrian hamster cell line AV12-664 (Burk et al. , supra ).
  • the thrombolytic potential of mt-PA6-V and its role in fibrinogen degradation and plasminogen degradation were examined using methods described by Jackson et al. , supra . These studies demonstrated that diglycosylated t-PA derivatives lacking the Finger, Growth Factor and Kringle 1 domains, such as mt-PA6-V, provide advantages over their partially glycosylated counterparts in the treatment of thromboembolic disorders. Although the monoglycosylated mt-PA6-P has a higher in vitro specific activity, the diglycosylated mt-PA6-V is a more efficient thrombolytic agent in vivo .
  • mt-PA6-V displays the unexpected and advantageous properties of causing less systemic conversion of plasminogen to plasmin, is markedly less prone to metabolism to its two-chain form, and has a higher fibrinolytic versus fibrinogenolytic ratio than mt-PA6-P. Surprisingly, mt-PA6-V also provides a greater maintenance of coronary blood flow and a faster time to reperfusion. Methods of treating thromboembolic disorders by the use of the diglycosylated form of t-PA derivatives that lack the Finger, Growth Factor and Kringle 1 domains, are disclosed in EP-A-493037.
  • the present invention describes how these advantageous properties can be imparted to t-PA derivatives, such as mt-PA6, by means other than glycosylation. This is of importance because when these derivatives are produced by recombinant DNA technology from eukaryotic cell cultures, only 10%-15% of the resulting molecules are diglycosylated.
  • the present invention makes it possible to convert the entire population of recombinantly produced t-PA derivatives that lack the Finger, Growth Factor and Kringle 1 domains to molecules having the enhanced thrombolytic properties of the diglycosylated form of the t-PA derivative molecule. Additionally, the economically disadvantageous process of separating the glycosylation forms in order to obtain only the diglycosylated form for use in in vivo thrombolytic therapy is avoided.
  • Adduct - a combination of two or more independently stable compounds.
  • Amphipathic molecule - a molecule that has both polar and nonpolar portions, said nonpolar portion comprising a C9-C15 straight or branched chain alkyl group and said polar portion comprising an anionic group.
  • the present invention provides adducts of human t-PA derivatives, wherein said adducts comprise a t-PA derivative that lacks the Finger, Growth Factor and Kringle 1 domains, bound to an amphipathic molecule.
  • the invention also provides methods for preparing said adducts and compositions for the treatment of thromboembolic disorders.
  • the present invention provides adducts of the formula X:R-A, wherein X is a nonglycosylated or monoglycosylated t-PA derivative that lacks the Finger, Growth Factor, and Kringle 1 domains; R is a C9 to C15 straight or branched chain alkyl group; and A is an anionic group.
  • a preferred group of the above adducts comprises those adducts wherein R is a C10 to C14 straight or branched chain alkyl group and A is selected from the group comprising: sulfate; sulfonate; phosphate; phosphonate; or a carboxylate anion.
  • a more preferred group of the above adducts comprise adducts wherein R is a C14 straight or branched chain alkyl group and A is selected from the group comprising: sulfate; sulfonate; phosphate; phosphonate; or a carboxylate anion.
  • An even more preferred group of the above adducts comprise adducts wherein R is a C14 straight or branched chain alkyl group and A is sulfate.
  • the most preferred adduct of the invention is wherein X is the t-PA derivative mt-PA6, R is a C14 straight or branched chain alkyl group, and A is a sulfate group.
  • amphipathic compounds useful in the formation of the adducts of the invention are C9-C15 alkyl sulfates, phosphates, sulfonates, phosphonates and carboxylates such as the anionic forms of the nonylsulfate, decylphosphonate, dodecylsulfate, tetradecylcarboxylate, undecylsulfate, pentadecylphosphate, and like fatty acids in the anionic form.
  • the anionic group may be bonded to the hydrocarbon chain at any position. It is possible that the hydrocarbon chain can contain olefinic bonds and may be substituted by two or more acidic groups in anionic form.
  • the anion portion A can be formed from one acid group of a dicarboxylic acid wherein the other carboxyl group forms an ester of a C9-C15 alcohol.
  • a dicarboxylic acid such as malonic acid, succinic acid, glutaric acid, adipic acid, and the like, can form the half ester with an alkyl alcohol such as dodecyl alcohol or decyl alcohol to form the half acid ester.
  • the latter is converted to the anionic form with a base, for example, sodium hydroxide or potassium hydroxide, to form the anionic salt form.
  • the anionic charge of the anionic portion A will, of course, vary with the nature of the acid group.
  • the anionic portion A may bear a mono or dinegative charge.
  • the present invention also provides a method for preparing the adduct X:R-A which comprises mixing said t-PA derivative X, with a compound of the formula R-A under conditions that allow the binding of R-A to X, wherein R is a C9 to C15 straight or branched chain alkyl group and A is an anionic group.
  • R is a C10 to C14 straight or branched chain alkyl group and A is selected from the group comprising: sulfate; sulfonate; phosphate; phosphonate; or a carboxylate anion.
  • R is a C14 straight or branched chain alkyl group and A is selected from the group comprising: sulfate; sulfonate; phosphate; phosphonate; or a carboxylate anion.
  • R is a C14 straight or branched chain alkyl group and A is sulfate.
  • X is the t-PA derivative mt-PA6.
  • R is a C14 straight or branched chain alkyl group
  • A is a sulfate group.
  • Example 2 of the present invention demonstrates that the difference in enzymatic activity of the monoand diglycosylated t-PA derivatives lacking the Finger, Growth Factor, and Kringle 1 domains is due to the presence of sialic acid residues at the terminus of the carbohydrate moieties on the t-PA derivative molecule. This is demonstrated by removal of these sialic acid residues with neuraminidase. When mt-PA6-V or mt-PA6-P was treated with neuraminidase, the specific activity of these molecules was converted to that of the nonglycosylated form of the mt-PA6.
  • the nonglycosylated form of mt-PA6 can be obtained from an Escherichia coli host cell which is transformed with a recombinant DNA expression vector that enables expression of mt-PA6.
  • E. coli is an organism that is incapable of producing glycosylated proteins.
  • the present invention provides that the contribution of the sialic acid residues to the fibrinolytic specific activity of the glycoforms of a t-PA derivative lacking the Finger, Growth Factor, and Kringle 1 domains can be duplicated by the addition of negative charge to this molecule.
  • the t-PA molecule has several hydrophobic regions characterized by linear arrays of nonpolar amino acids. Because of this hydrophobicity, amphipathic molecules can be hydrophobically bound to a t-PA derivative, such as mt-PA6. The amphipathic molecules mimic the effect of the sialic acid residues on the fibrinolytic specific activity of the t-PA derivative molecule. When amphipathic molecules are added to a mixture of mt-PA6 glycoforms, the mixture is converted to a population of mt-PA6 molecules with the specific activity of the diglycosylated mt-PA6-V molecule.
  • amphipathic molecules such as C9, C10, C12, C14, C16, and C18 alkyl sulfates were bound to the mt-PA6 molecules.
  • the C9, C16 and C18 alkyl sulfates did not have this effect.
  • Table 1 of Example 3 The results of this analysis are presented in Table 1 of Example 3.
  • alkyl sulfates The effect of these alkyl sulfates is due to the sulfate group because tetradecanol, which does not contain an anionic group, had no effect on the specific activity of mt-PA6-P. Additionally, binding of the C14 alkyl sulfate to neuraminidase-treated mt-PA6-P restores the fibrinolytic specific activity to the same value as that observed for mt-PA6-V. Binding studies with radiolabelled C14 alkyl sulfate and mt-PA6-P or mt-PA6-V demonstrated that one mole of C14 alkyl sulfate is bound per mole of mt-PA6.
  • the conditions for the binding of the t-PA derivative X, to the amphipathic compound R-A, as listed in Example 3, are merely illustrative. Conditions which optimize the binding of the t-PA derivative to the amphipathic compound should be chosen. Conditions such as temperature, pH, and the molar ratio of the t-PA derivative to the amphipathic compound, for example, may be varied in order to optimize the formation of the X:R-A adduct.
  • the present invention is also useful in converting t-PA derivatives that lack the Finger, Growth Factor and Kringle 1 domains, which are expressed and purified from prokaryotic host cells, such as Escherichia coli , to forms which have the properties of the diglycosylated form of the molecule.
  • the present invention is especially useful in this setting because prokaryotic host cells, such as E. coli , are incapable of glycosylating proteins.
  • the present invention provides a method for imparting the biological activity of the diglycosylated form of this t-PA derivative to a derivative obtained from a host cell incapable of glycosylating proteins.
  • t-PA6 is illustrative of such a t-PA derivative and is used herein to exemplify the usefulness of the present invention.
  • amphipathic molecules may be bound to the t-PA derivative by the method described in Example 3. The specific activity of these molecules is then measured by the method of Example 1. If further analysis is desired, these compounds may be analyzed by the methods described by Jackson et al. , supra .
  • thromboembolic disorders include deep vein thrombosis, disseminated intravascular coagulation, emboli originating from the heart or peripheral arteries, acute myocardial infarction, thrombotic strokes, and fibrin deposits associated with invasive cancers.
  • thromboembolic disorders can be treated by administration of a thrombolytically effective dose of an adduct, X:R-A, of the present invention.
  • the present invention thus provides a method for treating thromboembolic disorders in mammals which comprises administering to said mammal a thrombolytically effective dose of a t-PA adduct presented by the formula X:R-A.
  • the adducts of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby an adduct of the present invention is combined in admixture with a pharmaceutically acceptable carrier vehicle.
  • Suitable carrier vehicles and their formulation, inclusive of other human proteins, e.g. , human serum albumin, are described for example, in Remington's Phamaceutical Sciences 16th ed., 1980, Mack Publishing Co., edited by Oslo et al. .
  • Such compositions will contain an effective amount of an adduct of the present invention together with a suitable amount of carrier vehicle to prepare pharmaceutical compositions suitable for effective administration to the host.
  • Such compositions can be administered parentally, or by other means that ensure its delivery to the bloodstream in an effective form.
  • the preferred method of administration of an adduct of the present invention is by bolus intravenous administration.
  • Preferred dosages range from about 0.01 mg/kg to about 10 mg/kg. More preferred dosages range from about 0.1 mg/kg to about 1 mg/kg. The most preferred dosage is about 0.4 mg/kg.
  • mt-PA6 can be produced and isolated in accordance with the methods described by Burck et al. , supra . Fibrinolytic activity of the glycoforms of mt-PA6 was determined by a radial diffusion assay on a fibrin-agarose matrix plate (Schumacher and Schill, 1972, Anal. Biochem. 48:9-16). Small wells (6.5 mm) were cut into the fibrin-agarose matrix plate for sample application. Samples (20 ⁇ l) containing either mt-PA6 or reference standard t-PA, WHO Standard, batch 83/517 (Gaffey and Curtis, 1985, Throm. Haemostasis 53: 134-136), were placed in the precut wells of the plate.
  • IU Activity values
  • mt-PA6 samples were then incubated at 37°C in a moist oven for 16 hours.
  • Activity values were assigned to mt-PA6 samples by comparison of the areas of the clear lysis zones caused by the mt-PA6 samples to a standard curve of clear lysis zones of the t-PA standard plotted against the log of the t-PA concentration (3.75-15.0 IU/ml).
  • the protein content of mt-PA6 was determined using a computer-generated extinction coefficient (1.691 for a 1 mg/ml solution at 278 nm) derived from amino acid content of the enzyme.
  • samples of mt-PA6-P and mt-PA6-V were treated with neuraminidase (Boehringer mannheim, Indianapolis, IN.) as follows.
  • a 1.0 mg/ml (15 ⁇ M) solution of either mt-PA6-P or mt-PA6-V was dissolved in 5.0 ml of 0.05 M sodium acetate, pH 5.0.
  • 0.24 ml of a 1 IU/ml solution of neuraminidase was added and the reaction mixture was incubated at 37°C.
  • the progress of the reaction was monitored by chromatography of aliquots of the reaction mixture using a Mono S column on a Pharmacia FPLC system (800 Centennial Avenue, Piscataway, N.J. 08854). As the negatively charged sialic acid residues are removed from either mt-PA6-P or mt-PA6-V by the neuraminidase treatment, a later eluting (more positive) peak of mt-PA6 appears.
  • fibrinolytic specific activity of mt-PA6-P (1,300,00 IU/mg) and mt-PA6-V (780,000 IU/mg) is increased to 1,870,000 IU/mg and 1,810,000 IU/mg, respectively, by the removal of the sialic residues by neuraminidase. These specific activities are approximately the same as that observed for the nonglycosylated form of mt-PA6 expressed in Escherichia coli .
  • mt-PA6-P was incubated with straight chain C9, C12, C14 and C16 alkyl sulfates. Tetradecanol was used as a control.
  • the alkyl sulfates used in the exemplification of the present invention were prepared as described by Sobel et al. , 1941, J. Am. Chem Soc. 63:1159-1161.
  • Table 1 Sample Activity Fibrinolytic Specific mt-PA6-P 1,300,000 IU/mg mt-PA6-P + C8 alkyl sulfate 1,310,000 IU/mg mt-PA6-P + C12 alkyl sulfate 850,000 IU/mg mt-PA6-P + C14 alkyl sulfate 654,000 IU/mg mt-PA6-P + C16 alkyl sulfate 1,300,000 IU/mg mt-PA6-P + tetradecanol 1,320,000 IU/mg
  • the data of Table 1 demonstrate that the introduction of negative charge by these amphipathic molecules has a profound effect in the fibrinolytic specific activity of the mt-PA6 molecule.
  • the specific activity of the mt-PA6:C14 sulfate adduct is the same as that of mt-PA6-V.
  • the mt-PA6 adduct may be isolated and purified by chromatography according to the method of Burck et al. , supra. , to separate the mt-PA6:C14 sulfate adduct from the excess C14 sulfate in the reaction mixture.
  • mt-PA6-P or mt-PA6-V molecules were treated with neuraminidase, as described in Example 2, to remove the sialic acid residues from the mt-PA6 molecules.
  • Each mt-PA6/neuraminidase reaction mixture was then adjusted to pH 3.0 with HCl, and a 10-fold molar excess (25 mM) of tetradecyl sodium sulfate was added.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP92305336A 1991-06-13 1992-06-11 Verbindungen und Verfahren zur Behandlung thromboembolischer Störungen Expired - Lifetime EP0518652B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/714,537 US5272076A (en) 1991-06-13 1991-06-13 Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA
US714537 1991-06-13

Publications (2)

Publication Number Publication Date
EP0518652A1 true EP0518652A1 (de) 1992-12-16
EP0518652B1 EP0518652B1 (de) 1997-01-08

Family

ID=24870421

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92305336A Expired - Lifetime EP0518652B1 (de) 1991-06-13 1992-06-11 Verbindungen und Verfahren zur Behandlung thromboembolischer Störungen

Country Status (9)

Country Link
US (1) US5272076A (de)
EP (1) EP0518652B1 (de)
JP (1) JPH05184365A (de)
AT (1) ATE147409T1 (de)
CA (1) CA2071145A1 (de)
DE (1) DE69216479T2 (de)
DK (1) DK0518652T3 (de)
ES (1) ES2096035T3 (de)
GR (1) GR3022779T3 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293934A1 (de) * 1987-06-04 1988-12-07 Zymogenetics, Inc. Mutierter t-PA mit Kringle-Ersatz
WO1991013149A1 (en) * 1990-03-01 1991-09-05 Genentech, Inc. Tissue plaminogen activator having fibrin specific properties

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4929560A (en) * 1988-02-03 1990-05-29 Damon Biotech, Inc. Recovery of tissue plasminogen activator
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293934A1 (de) * 1987-06-04 1988-12-07 Zymogenetics, Inc. Mutierter t-PA mit Kringle-Ersatz
WO1991013149A1 (en) * 1990-03-01 1991-09-05 Genentech, Inc. Tissue plaminogen activator having fibrin specific properties

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 113, no. 15, October 8, 1990, Columbus, Ohio, USA WU, Z. et al. "Pharmacokine- tics and coronary thromboly- tic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first Kring- le domains(amino acids 6-173) in a canine model" page 11, column 2, abstract- no. 125 986j *
CHEMICAL ABSTRACTS, vol. 114, no. 25, June 24, 1991, Columbus, Ohio, USA MATTSON, C. et al. "Synergism between tissue-type plasmino- gen activator and a geneti- cally engineered variant lacking the finger domain, the growth factor domain and the first kringle domain" page 538, column 1, abstract- no. 244 997u *
CHEMICAL ABSTRACTS, vol. 115, no. 23, December 9, 1991, Columbus, Ohio, USA LANGER-SAFER, PENNINA R. et al. "Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmaco- logical characterization of a novel chimera containing a high affinity fibrin-bin- ding domain linked to a heterologous protein" page 43, column 2, abstract- no. 247 712d *

Also Published As

Publication number Publication date
EP0518652B1 (de) 1997-01-08
ES2096035T3 (es) 1997-03-01
CA2071145A1 (en) 1992-12-14
ATE147409T1 (de) 1997-01-15
DE69216479D1 (de) 1997-02-20
US5272076A (en) 1993-12-21
DE69216479T2 (de) 1997-05-15
GR3022779T3 (en) 1997-06-30
DK0518652T3 (da) 1997-06-30
JPH05184365A (ja) 1993-07-27

Similar Documents

Publication Publication Date Title
JP3459416B2 (ja) 修飾されたファクター▲ｖｉｉ▼
AU666104B2 (en) Recombinant agents affecting thrombosis
JP3330932B2 (ja) 抗凝固剤タンパク質
JPH08510746A (ja) 改良型▲ｖｉｉ▼因子
WO1988010295A1 (en) MODIFIED FACTOR VII/VIIa
Collen et al. Tissue-type plasminogen activator
WO1996013274A1 (en) Process for production of inhibited forms of activated blood factors
US5650314A (en) Recombinant agents affection thrombosis
Shih et al. Plasminogen and plasminogen activator assembly on the human endothelial cell
EP0518652B1 (de) Verbindungen und Verfahren zur Behandlung thromboembolischer Störungen
EP0324597A2 (de) Fibrin-Selektiv-Doppelketten-Plasminogen-Aktivator
US5595736A (en) Compounds and methods for treatment of thromboembolic disorders
US6869778B2 (en) Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
EP0662513B1 (de) Verfahren zur Verhinderung der Zersetzung des Proteins C
US5688664A (en) Thrombin activatable plasminogen analogues
EP0336508A1 (de) Rekombinanter Mutant des menschlichen Einzelketten-Urokinase Plasminogen-Aktivator Types, hergestellt durch gerichtete Mutagenese von Lysin 158 zu Histidin 158
NZ257175A (en) Thrombin activated plasminogen derivatives with the cleavage site p4-p3-pro-arg-p1'-p2'
Toki et al. Kinetic studies of three different molecular forms of urokinase for the activation of native human plasminogen
US5908625A (en) Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
EP0917567A1 (de) Thrombinaktivierbarer plasminogenaktivator
EP0400054A1 (de) Für modifizierte tpa-moleküle kodierende gensequenzen und deren produkte
EP0796323A1 (de) Verwendung der proteasedomäne humanes gewebsplasminakilivators für die behandlung von thromboembolischen erkrankungen
EP0272315A1 (de) Rekombinante zubereitung des plasminogenaktivators von menschlichem gewebe
WO1999009185A1 (de) Plasminogenaktivator mit verbesserter zymogenität
MXPA99000966A (en) Plasminogen activator capable of being activated by thrombin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL PT SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19960423

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL PT SE

REF Corresponds to:

Ref document number: 147409

Country of ref document: AT

Date of ref document: 19970115

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

ET Fr: translation filed
REF Corresponds to:

Ref document number: 69216479

Country of ref document: DE

Date of ref document: 19970220

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2096035

Country of ref document: ES

Kind code of ref document: T3

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3022779

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20010314

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010319

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20010327

Year of fee payment: 10

Ref country code: LU

Payment date: 20010327

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20010405

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20010420

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20010502

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20010503

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20010531

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20010613

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20010627

Year of fee payment: 10

Ref country code: CH

Payment date: 20010627

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20010713

Year of fee payment: 10

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020611

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020611

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020612

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020630

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020731

BERE Be: lapsed

Owner name: *ELI LILLY AND CY

Effective date: 20020630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021231

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030101

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030101

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20020611

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030228

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20030101

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20021231

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050611